Insider · CIK 0001376847
Daniel J. O'Connor
Files at DMAC (DiaMedica Therapeutics Inc.), AMAM (Ambrx Biopharma, Inc.). First filing Oct 31, 2023, latest Oct 31, 2023.
In brief
Daniel J. O'Connor files SEC Form 4 as director, CEO and president at AMAM (Ambrx Biopharma, Inc.), and also at DMAC (DiaMedica Therapeutics Inc.). Since Oct 31, 2023, Daniel J. O'Connor has reported 0 open-market buys worth $0 and 1 open-market sell worth $491k, the latest filed on Oct 31, 2023.
A track record needs three past buys with six months of prices behind them; Daniel J. O'Connor has 0, so none is measured yet.
The newest scored trade: sold $491k of AMAM on Oct 27, 2023, filed Oct 31, 2023, scored 36 (weak), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Ambrx Biopharma, Inc. | $491k 50,012 shares | -13% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 1, 2023 | Ambrx Biopharma, Inc. | 50,012 0.08% of outstanding | $491k | Oct 27, 2023 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +40,412 | $0.00 | $0 | 40,412 | Jun 3, 2026 |
| Feb 20, 2025 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +64,242 | $0.00 | $0 | 64,242 | Feb 24, 2025 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Common Stock | -48,202 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -294,643 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -750,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -772,857 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -173,785 | - | - | 0 | Mar 7, 2024 |
| Dec 11, 2023 | AMAM Ambrx Biopharma, Inc. | AGrant or award Common Stock | +750,000 | $0.00 | $0 | 1,363,332 | Dec 11, 2023 |
| Oct 27, 2023 | AMAM Ambrx Biopharma, Inc. | SOpen-market sale Common Stock10b5-1 | -50,012 | $9.82 | $491k | 342,845 | Oct 31, 2023 |
Questions about Daniel J. O'Connor
Answered from the filings on this page, as of the latest one.
Is Daniel J. O'Connor buying or selling?
Not in the last 12 months. Daniel J. O'Connor's latest open-market trade on SEC Form 4 was sold $491k of AMAM on Oct 27, 2023.
How did Daniel J. O'Connor's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel J. O'Connor has 0.
Where does Daniel J. O'Connor file Form 4?
Daniel J. O'Connor has filed Form 4 at AMAM (Ambrx Biopharma, Inc.) as President and CEO; DMAC (DiaMedica Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.